KNIGHT GLADE M
Known title: Executive ChairmanCIK: 0001113158
KNIGHT GLADE M's purchase track record
How the stock did after each of KNIGHT GLADE M's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
14
of 15 since November 9, 2021
Stock higher 6 months later
71%
3 months: 53%
Median 6-month return
+3.0%
3 months: +1.7%
Beat the S&P 500
50%
median -0.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/11/2026 | APLE | $70K | +15.6% | pending | — |
| 12/11/2025 | APLE | $60K | +1.7% | +41.0% | +7.1% |
| 8/19/2025 | APLE | $61K | -4.9% | +3.2% | +6.7% |
| 5/6/2025 | APLE | $114K | +5.7% | +2.8% | +20.8% |
| 2/27/2025 | APLE | $73K | -17.0% | -6.1% | +10.9% |
| 8/8/2024 | APLE | $70K | +13.1% | +17.0% | +14.4% |
| 5/21/2024 | APLE | $74K | -2.4% | +8.7% | +11.2% |
| 8/11/2023 | APLE | $75K | +8.1% | +11.7% | +12.6% |
| 5/5/2023 | APLE | $77K | -1.4% | +12.4% | +5.4% |
| 2/27/2023 | APLE | $84K | -11.2% | -8.0% | +11.3% |
| 11/10/2022 | APLE | $81K | +8.3% | -2.4% | +4.4% |
| 8/9/2022 | APLE | $81K | -2.7% | +11.8% | +1.0% |
| 5/16/2022 | APLE | $81K | +6.7% | +1.6% | -1.3% |
| 2/28/2022 | APLE | $88K | -4.7% | -7.1% | -7.8% |
| 11/9/2021 | APLE | $80K | +3.3% | +2.5% | -14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| APLE | ▲ Buy | Open Market | 5,000 | $70K | 5/11/2026 | View on chart |
| APLE | ▲ Buy | Grant | 18,779 | $227K | 3/3/2026 | View on chart |
| APLE | ▲ Buy | Grant | 11,894 | $0 | 3/3/2026 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $60K | 12/11/2025 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $61K | 8/19/2025 | View on chart |
| APLE | ▲ Buy | Open Market | 10,000 | $114K | 5/6/2025 | View on chart |
| APLE | ▲ Buy | Grant | 33,036 | $478K | 3/4/2025 | View on chart |
| APLE | ▲ Buy | Grant | 15,318 | $0 | 3/4/2025 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $73K | 2/27/2025 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $70K | 8/8/2024 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $74K | 5/21/2024 | View on chart |
| APLE | ▲ Buy | Grant | 25,377 | $0 | 3/1/2024 | View on chart |
| APLE | ▼ Sell | Tax Withholding | 7,841 | $128K | 3/1/2024 | View on chart |
| APLE | ▲ Buy | Grant | 44,308 | $721K | 3/1/2024 | View on chart |
| APLE | ▼ Sell | Tax Withholding | 7,963 | $135K | 12/8/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $75K | 8/11/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 2,500 | $39K | 5/5/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 2,500 | $39K | 5/5/2023 | View on chart |
| APLE | ▲ Buy | Grant | 39,994 | $668K | 3/1/2023 | View on chart |
| APLE | ▲ Buy | Grant | 20,022 | $0 | 3/1/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 4,900 | $83K | 2/27/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 100 | $2K | 2/27/2023 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $81K | 11/10/2022 | View on chart |
| APLE | ▲ Buy | Open Market | 3,257 | $53K | 8/9/2022 | View on chart |
| APLE | ▲ Buy | Open Market | 1,743 | $28K | 8/9/2022 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $81K | 5/16/2022 | View on chart |
| APLE | ▲ Buy | Grant | 39,065 | $695K | 3/2/2022 | View on chart |
| APLE | ▲ Buy | Grant | 19,039 | $0 | 3/2/2022 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $88K | 2/28/2022 | View on chart |
| APLE | ▲ Buy | Open Market | 5,000 | $80K | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
APLE: No Relevant News in Last 7 Days
The only news item in the last week was about a health care stock that received a positive endorsement from Jim Cramer. This development does not involve Apple Hospitality REIT, so there are no direct implications for APLE. Investors can continue to monitor the company’s fundamentals and market levels as usual.
APLE: No Relevant News in Last 7 Days. The only news item in the last week was about a health care stock that received a positive endorsement from Jim Cramer. This development does not involve Apple Hospitality REIT, so there are no direct implications for APLE. Investors can continue to monitor the company’s fundamentals and market levels as usual.